The PI3K subunits, P110α and P110β are potential targets for overcoming P-gp and BCRP-mediated MDR in cancer.

导出 OA

翻译打印收藏纠错

作者： Lei,Zhang ^[1] ; Yidong,Li ^[2] ; Qianchao,Wang ^[2] ; Zhuo,Chen ^[1] ; Xiaoyun,Li ^[3] ; Zhuoxun,Wu ^[2] ; Chaohua,Hu ^[4] ; Dan,Liao ^[2] ; Wei,Zhang ^[5] ; Zhe-Sheng,Chen ^[2]

作者单位： State Key Laboratory of Structural Chemistry, Fujian Institute of Research on the Structure of Matter, Chinese Academy of Sciences, Fuzhou, 350002, China. ^[1] Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John's University, Queens, NY, 11439, USA. ^[2] State Key Laboratory of Structural Chemistry, Fujian Institute of Research on the Structure of Matter, Chinese Academy of Sciences, Fuzhou, 350002, China. zchen@fjirsm.ac.cn. ^[3] College of Traditional Chinese Medicine, Jinan University, Guangzhou, 510632, Guangdong, China. ^[4] College of Agriculture, Fujian Agriculture and Forestry University, Fuzhou, 350002, China. ^[5] Key Laboratory of Complementary and Alternative Medicine Experimental Animal Models of Guangxi, Guangxi University of Chinese Medicine, Nanning, 530200, China. ^[6] Institute of Plastic Surgery, Weifang Medical University, Weifang, China. ^[7] Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John's University, Queens, NY, 11439, USA. chenz@stjohns.edu. ^[8]

关键词 Breast cancer resistance protein (BCRP/ABCG2/ABCP/MXR)Cancer Multidrug resistance (MDR)P-glycoprotein (P-gp/ABCB1/MDR1)P110α/PIK3CA P110β/PIK3CB PI3K Reversal of MDR